sb 203580 has been researched along with mitopodozide in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (mitopodozide) | Trials (mitopodozide) | Recent Studies (post-2010) (mitopodozide) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 66 | 2 | 0 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brodbeck, K; Häring, HU; Pfeiffer, A; Sauer, U; Schleicher, ED; Weigert, C | 1 |
1 other study(ies) available for sb 203580 and mitopodozide
Article | Year |
---|---|
AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter in mesangial cells.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation; Glomerular Mesangium; Glucose; Humans; Hyperglycemia; Imidazoles; Indoles; Maleimides; Mitogen-Activated Protein Kinases; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Podophyllin; Podophyllotoxin; Promoter Regions, Genetic; Pyridines; RNA, Messenger; Sp1 Transcription Factor; Tetradecanoylphorbol Acetate; Tissue Distribution; Transcription Factor AP-1; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2000 |